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Abstract
Purpose of review
Myotonic dystrophy type 1 is a multisystemic disorder caused by
a noncoding triplet repeat. The age of onset is variable across the
lifespan, but in its most severe form, the symptoms appear at birth
(congenital myotonic dystrophy) or in the pediatric age range
(childhood-onset myotonic dystrophy). These children have
a range of disabilities that reduce the lifespan and cause signiﬁcant
morbidity. Currently, there are no agreed upon recommendations
for caring for these children.
Recent findings
TheMyotonic Dystrophy Foundation recruited 11 international clinicians who are experienced
with congenital and childhood-onset myotonic dystrophy to create consensus-based care
recommendations. The experts used a 2-step methodology using elements of the single text
procedure and nominal group technique. Completion of this process has led to the de-
velopment of clinical care recommendations for this population.
Summary
Children with myotonic dystrophy often require monitoring and interventions to improve the
lifespan and quality of life. The resulting recommendations are intended to standardize and
improve the care of children with myotonic dystrophy.
Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder caused by a toxic CTG
repeat expansion in the 39UTR of the DMPK gene.1–3 In adults with DM1, symptoms are
characterized by progressive distal muscle weakness, myotonia, early onset cataracts, cardiac and
gastrointestinal problems, and dysfunction in the CNS.4,5 The multiorgan involvement is often
more pronounced and with earlier onset in individuals with symptom onset in childhood. The age
of onset of DM1 is variable, and intergenerational repeat expansion (known as anticipation) may
result in symptom onset during childhood. When symptom onset occurs at birth, this is known as
congenital onset myotonic dystrophy (CDM). Symptom onset after the newborn period and up to
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18 years of age is typically referred to as childhood-onset myo-
tonic dystrophy (ChDM). However, alternate deﬁnitions des-
ignate further cut points depending on age of onset.6,7 Although
the exact global prevalence is unknown, children with CDM
likely represent 10%–30% of the overall DM1 population.4,8
These disorders cause signiﬁcant morbidity and mortality.
Children with CDM often require intensive intervention at
birth because of hypotonia, respiratory failure, and feeding
diﬃculties.4,9 For children with CDM ventilated longer than
3 months, there is a 30% mortality in the ﬁrst year of life.10
Both children with CDM and ChDM may have symptoms
associated with attention deﬁcit hyperactivity disorder or autism
spectrum disorder (sometimes referred to as social communi-
cation disorder) during childhood.11,12 They also have signiﬁ-
cant motor delays13 and may have intractable irritable bowel
symptoms, including incontinence. Previous research suggests
that 88% of individuals with congenital or childhood-onset
myotonic dystrophy are unemployed over the age of 18 years.14
Themultisystemicnature,morbidity, andmortality associatedwith
congenital and childhood-onset myotonic dystrophy necessitate
the development of care recommendations to standardize care.
These consensus-based recommendations will also set the foun-
dation for innovative clinical initiatives where gaps exist and also
further research to improve aspects of management. These care
recommendations may also better prepare the pediatric DM1
community for future clinical trials because variation in clinical care
may have signiﬁcant eﬀects on the outcome of children partici-
pating in geographically dispersed clinical research sites.
Methods
Participant recruitment
The Myotonic Dystrophy Foundation recruited clinicians
from the United States, Canada, and Europe who have ex-
perience in the treatment of children with DM1 to develop
consensus-based recommendations.
Consensus approach
As previously described, the Myotonic Dystrophy Founda-
tion developed a two-phase consensus buildingmethodology
using components of the single text procedure and nominal
group technique.15 This approach was chosen given both the
sparsity of literature surrounding many of the clinical aspects
and the extensive experience of the clinicians in this area.
Three of the authors (N.E.J., C.C., and E.Z.) created the
initial draft document, drawing from the existing literature
and clinical practice that served as an initial text for the rec-
ommendation developments.
After creation of the single text, stakeholders were engaged
to reﬁne the recommendations through a consensus-based
approach. The experts were initially assigned to speciﬁc areas of
recommendations, where they reﬁned the recommendations. A
facilitator (LH) then lead a series of meetings to review, revise,
and ﬁnalize the recommendations with the entire author panel.
These eﬀorts led to the ﬁnal consensus-based care recom-
mendations along with a quick reference guide. The care rec-
ommendations are divided into 2 main sections, the General
Care Considerations and Systems-based Approach to Manage-
ment. Because there are diﬀerences between childhood-onset
and congenital-onset DM1, recommendations speciﬁc to CDM
are separated throughout the document. The Quick Reference
Guide is provided as an appendix, and the full document is
available online (appendix e-1, links.lww.com/CPJ/A89). Both
feature ﬂowcharts and other infographics for ease of use.
Results
See full recommendations at Neurology.org/cp.
General care considerations
Diagnosis and classification
c The diagnosis of DM1 should be suspected in any child
with a family history of DM1 and/or presenting with
one or more of the following features:
◦ Eyelid ptosis and/or oral motor weakness
◦ Distal weakness, primarily of the ﬁnger and wrist ﬂexors,
without contractures, or weakness of the neck ﬂexors
◦ Myotonia or “stiﬀness” of muscles
◦ Autistic features or social communication diﬃculties
◦ Attention deﬁcit disorder, anxiety, and other behav-
ioral problems
◦ Developmental delay and/or Intellectual disability
The age of onset of DM1 is variable,
and intergenerational repeat
expansion (known as anticipation)
may result in symptom onset during
childhood.
The multisystemic nature, morbidity,
and mortality associated with
congenital and childhood-onset
myotonic dystrophy necessitate the
development of care
recommendations to standardize and
improve the care of this population.
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◦ Learning disabilities (e.g., dyslexia, dyscalculia)
◦ Excessive daytime sleepiness (EDS)
◦ Gastrointestinal issues: constipation or diarrhea
◦ Scoliosis
◦ Arrhythmia
◦ Prolonged recovery or respiratory arrest after anesthesia
◦ Neonatal features of hypotonia, weakness, club foot,
respiratory distress, or feeding problems
c The classiﬁcation of congenital and childhood-onset
DM1 is provided in table 1 in Quick Reference Guide.
Note that diagnosis may be made retrospectively after
reviewing symptom onset. Fetal tissue with long CTG
repeats should not be called CDMbecause this diagnosis
is reserved for newborns. In these cases, we would
suggest use of fetal DM1 as more appropriate.
c Genetic counseling is recommended for patients
exhibiting clinical signs indicative of DM1, or have at-
risk family members, to enable them to make an
informed decision about whether to proceed to genetic
testing. Individuals with 37–49 CTG repeats are
deemed very unlikely to develop detectable DM1
symptoms. However, such “premutations” can expand
into the disease range in subsequent generations,
particularly when transmitted by women. Individuals
thus identiﬁed should be oﬀered genetic counseling
(see Genetic counseling) to discuss their risk for
transmitting DM1.
Genetic counseling
c Referral to genetic counseling (see nsgc.org) is recom-
mended for all patients with congenital and childhood-
onset DM1 and their parents and to assess the parents for
the diagnosis of DM1.
c Genetic counseling in aﬀected families should convey
information about:
◦ The inheritance pattern of disease (autosomal
dominant inheritance)
◦ The wide variability in the scope and severity of DM1
symptoms, even within the same family
◦ The possibility of changes in symptom scope and
severity over time
◦ The likelihood that the mutation will expand and the
disease will become more severe as it is passed from
generation to generation (anticipation)
◦ Particular attention to the possibility of a minimally
aﬀected mother giving birth to a severely aﬀected child
◦ Options for family planning
c Do not use CTG repeat numbers, if available, for genetic
advice or prognostication; these need to be discussed
with a genetic counselor. Speciﬁcally, repeat size may be
an indicator of severity, but it does not provide any
information about the prognosis.
Focus on CDM
c Once a family has had a child with CDM, there is an
increased risk that the next aﬀected child with DM1 is
likely to have congenital form as well.
Neonatal care
 A high-risk obstetrician should provide prenatal obstetric
care for mothers known or suspected to carry a child with
DM1.
 Pediatric or neonatal specialist should be present at
delivery if a mother is known to have DM1 or if the child
is known or suspected to have DM1.
Focus on CDM
 Children with CDM will often need management in
a neonatal intensive care unit with the capability to deal
with breathing and feeding support. This team requires
a range of neonatal and consulting specialists who can
manage the genetic, respiratory, gastrointestinal, or-
thopedic, neuromuscular, neurosurgical, and cardiac
issues. See ﬁgure 1 in Quick Reference Guide for
neonatal care.
End of life counseling and management
 Recommend the introduction of palliative care at the
time of diagnosis and at regular intervals thereafter. When
a formal pediatric palliative care team is available, they
should be consulted.
 Recognize and address caregiver burden, whether the
caregiver has DM1, oﬀering respite care or equivalent
measures to patient to improve family support. Address
normal grief on the part of the patient and family and
oﬀer counseling as appropriate.
 Establish an emergency health care plan and advance
directives with the family.
Focus on CDM
 Introduce the concept that the natural history of the
disease includes progressive improvement of strength for
the ﬁrst decade of life; however, the complications of
CDM can be critical and have a high risk of mortality,
particularly in the ﬁrst year of life.
 Advise families or caregivers that invasive and non-
invasive ventilation (NIV) and nutrition through gastro-
stomy tube are acceptable parts of care for patients with
CDM.
Surgery and anesthesia
 Inform all caregivers that anyone administering an
anesthetic should be aware of the DM1 diagnosis.
 When possible combine procedures under a single
sedation.
 Arrange for a preanesthetic visit for all children planning
to have deep sedation for a diagnostic test, procedure,
or surgery. If possible, include a pulmonologist with
expertise in neuromuscular diseases during this visit.
 Even if the patient has mild DM1, monitoring for a longer
period of time than is typical following anesthesia or
surgery will allow for identifying serious adverse events in
the hospital setting.
 Providers are encouraged to review the Myotonic
Dystrophy Foundation Practical Suggestions for the
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Anesthetic Management of a Myotonic Dystrophy Patient
(myotonic.org/sites/default/ﬁles/MDF_LongForm_
AnesGuidelines_01C.pdf) for anesthesia risks and
recommendations before any surgeries or procedures
requiring anesthesia and the Anesthesia Quick Reference
Guide (myotonic.org/sites/default/ﬁles/MDF Anes-
thesia Guidelines FNL 2016 2 2. pdf). These docu-
ments should be reviewed before treatment decisions.
Focus on CDM
 It is worth noting that children with CDM are at a higher
risk of anesthetic complications, given the underlying
respiratory involvement, as opposed to those with
childhood-onset myotonic dystrophy.
Systems-based approach
to management
Respiratory
 Signs of respiratory problems in children with myotonic
dystrophy include ineﬀective cough, recurrent pulmo-
nary infections, orthopnea, dyspnea, poor sleep, morning
headaches, apnea, fatigue, and snoring.
 See ﬁgure 2 in Quick Reference Guide for a ﬂowchart of
testing and treatment options in congenital and
childhood-onset myotonic dystrophy.
Focus on CDM
 For CDM children who remain on longer term trach
ventilation, there is often improvement in respiratory
strength over time, and consideration to decannulate
a tracheostomy should be made after careful consideration
with the multidisciplinary team including neurology;
respirology; ear, nose, and throat; and the family.
Consideration of airway control, respiratory infection
frequency, ability to tolerate a facial or nasal mask for NIV
and compliance and cooperation with maintenance
pulmonary therapy such as cough assist, breathe staking,
etc. Testing for hypoventilation in sleep should be done
before decannulation.
Cardiovascular
c Inform families of the risks of arrhythmias and cardiac
dysfunction and the importance of prompt medical
attention if symptoms are observed (i.e., palpitations,
presyncope, syncope, dyspnea, chest pain, unexplained
fatigue).
◦ A 12-lead ECG should be performed at DM1 diagnosis,
and if normal and the patient remains asymptomatic, ECG
should be performed annually and warrants more
investigation if the patient is symptomatic.
◦ If the ECG is normal and clinical suspicion is high, a
24-hour Holter monitor may be considered as
a second-line investigation.
◦ Because speciﬁc medications such as mexiletine and
psychostimulants are antiarrhythmic, an ECG before
use, again within 3 months of starting therapy, and
then at serial intervals is recommended.
◦ Consider in-hospital cardiac monitoring to detect
arrhythmias if admitted for longer duration than
typical after surgical procedures or if admitted due to
severe illness or infection
c For young DM1 patients, serial exercise stress testing
and signal-averaged ECGs may be considered.
c Evaluate and treat using American Heart Association
(AHA) Management of Cardiac Involvement Associated
With Neuromuscular Diseases A Scientiﬁc Statement From
the American Heart Association 2017 circ.ahajournals.
org/content/136/13/e200.long and ACC ([American
College of Cardiology]/AHA)/ESC (European Society
of Cardiology) Guidelines for Management of Patients
with Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death (see ncbi.nlm.nih.gov/pubmed/
16949478)- section on pediatric issues 13.4.
Skeletal muscle weakness, orthopedic
complications, and rehabilitation
c Children should be evaluated early and often for
physical, occupational, and speech therapy needs with
speciﬁc attention to:
◦ Feeding concerns and dysphagia
◦ Gross motor delay
◦ Gross and ﬁne motor weakness
◦ Dysarthria and potential augmentative and alternative
communication needs
◦ Language acquisition delays
c The spine should be assessed for scoliosis and, if
necessary, consider bracing or referral to orthopedic
surgeon.
c Children should be encouraged to participate in speech
therapy targeting speech, language, and communication
from a very early age.
Focus on CDM
 Newborns with CDM often having diﬃculty feeding and
alternative nutrition should be considered. After about
a year of actively working with a speech therapist or
occupational therapist, most children can generally start
on oral feeding.
 Children with CDM experience progressive improve-
ment in their proximal strength until adolescence, at
a minimum. Therefore, children should be encouraged to
participate in physical activities.
 Prevention of joint contractures are key to management
and should be closely monitored with early initiation of
stretching. Treatment of talipes equinovarus and other
joint contractures should include initial stretching
regimen and appropriate ankle bracing (for talipes
equinovarus). Serial casting may be considered.
Skeletal muscle myotonia
c Delayed relaxation after grip or percussion, diﬃculty
related to activities of daily life, progressive speech
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impairment, or profound irritable bowel symptoms are
signs often related to myotonia.
c Mexiletine (Mexitil) is an option for myotonia, if it is
demonstrated and is distressing to the patient. Mexiletine
may not be approved for use in every country. In these cases,
other sodium channel antagonists may be considered.
◦ Because mexiletine is an antiarrhythmic, an ECG
before use, again within 3 months of starting therapy,
and then at serial intervals is recommended.
◦ Instruct the patient to avoid dyspepsia and transient
“dizzy feelings” associated with mexiletine treatment
by taking it with food to extend absorption and lower
peak level in blood.
Ocular and hearing management
 Baseline audiometry should be performed, especially at
school age.
 Ophthalmologic assessment should be performed at
diagnosis and at least yearly to evaluate for hyperopia,
stigmatism, strabismus, and visual acuity to prevent
evolution of visual impairment.
 Eyelid ptosis; if ptosis becomes severe and interferes with
vision, intervention such as eyelid “crutches” that can be
inserted into glasses may be warranted. Try crutches as
a remedy for ptosis before eyelid surgery is considered
because of anesthesia risks. Ophthalmic lubricants for dry
eye may be considered.
Gastrointestinal and
genitourinary management
c Presence of gastrointestinal symptoms such as abdom-
inal pain, constipation, fecal incontinence, or diarrhea
may be a frequent problem. The symptoms may mimic
irritable bowel syndrome (IBS).15 Fiber supplementa-
tion (more than 8 g daily) is the ﬁrst-line treatment.
c Gentle laxatives (see below) for constipation. Oils
should be avoided as they will lead to diarrhea. If
a patient does not respond to the ﬁrst- or second-line
recommendations below, a referral to a gastrointestinal
specialist for anal manometry should be considered:
◦ First-line therapy recommendations: polyethylene
glycol (Miralax), senna (Ex-Lax, Senokot), docusate
(Colace), or lactulose (Cholac)
◦ Second-line therapy recommendations: bisacodyl
(Dulcolax, Correctol), lubiprostone (Amitiza), or
linaclotide (Linzess)
◦ Metoclopramide (Reglan) may be used to reduce the
symptoms of gastroparesis, pseudo-obstruction, and
gastric reﬂux. Providers should be aware of the risk of
acute dystonic reactions with this medication. Long-
term use is not recommended because this drug can
cause tardive dyskinesia.
◦ Cholestyramine and loperamide are other options in
the presence of mainly diarrhea and anticholinergic
drug such as hyoscyamine sulfate in the presence of
IBS. Because anticholinergic drugs may be antiar-
rhythmic, see Cardiac section on management.
◦ Mexiletine may be considered for refractory diarrhea
or constipation because the drug may be antiarrhyth-
mic, see Cardiac section on management.
c If bacterial overgrowth is found on breath testing,
treating with antibiotics may reduce diarrhea.
Focus on CDM
 As mentioned in the neonatal care section, children with
CDMmay require a temporary feeding tube. If dysphagia
persists, consider enteral nutrition. Refer to speech therapy.
Children should be periodically re-assessed for improving
dysphagia.
 Children with CDMoften beneﬁt from dysphagia therapy.
With aggressive dysphagia therapy, children with CDM
often are able to feed orally within the ﬁrst year of life.
Neurodevelopmental management
Recommendations
c Neuropsychological testing should be performed in
every child with DM1 to delineate cognitive strengths
and weaknesses. This may include the following:
◦ Psychometric assessment of global intellectual ability
and adaptive functioning
◦ Assessment of executive functions
◦ Assessment of social cognition
◦ Assessment of visuomotor integration and visuospatial
ability
◦ Assessment of receptive and expressive language abilities
◦ Assessment of EDS
◦ Assessment of learning disabilities (speciﬁc tests for
dyscalculia, dyslexia, and dyspraxia)
c The assessments should be performed in the congenital
form in preschool age and should be repeated, depend-
ing on the level of functioning, 2–3 times before
adulthood. In childhood DM1, neuropsychological
testing is recommended at diagnosis and repeated in
preschool or school age and college period.
c Patients with psychiatric or behavioral issues should be
referred to a mental health care professional for
assessment of Autism Spectrum Disorders, Attention
Deﬁcit disorders with or without Hyperactivity, alex-
iythmia, and other behavioral problems.
c Psychostimulants may be beneﬁcial if attention deﬁcits
are associated with an impairing level of fatigue or EDS
(see excessive daytime sleepiness). As psychostimulants
may be proarrhythmic, see Cardiac section on stimulant
management:
◦Serotonin-enhancing antidepressants if excessive anxiety
or other treatable psychiatric symptoms are present
◦Speciﬁc cognitive remediation programs to enhance social
emotional abilities (visual contact, joint attention, emotional
regulation) or executive functions eﬃciency (inhibitory
control, attention, working memory, and cognitive ﬂexibil-
ity) using dedicated software (e.g., Cogmed®)
c Language remediation and reading therapy should be
considered because of the presence of cognitive deﬁcits,
even in children with normal intelligence. Attention deficit,
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fatigability, and visual–spatial construction dysfunction
can result in speciﬁc learning disorders with impair-
ment in reading and spelling as well as in mathematics.
Psychosocial management
 Healthcare professionals have a responsibility to co-
ordinate specialist care and support services for children
with DM1. There is a need to be alert to the psychological
and social dysfunctions and monitor home and educa-
tional circumstances. Liaison between agencies is essential
to ensure a consistent approach between health, education,
and social care agencies.
 Children with DM1 should have access to appropriate
psychological and therapy services at an early age to ensure
they are fulﬁlling their maximum potential and learning
coping strategies for later life. The modiﬁcation of activities
including social engagement strategies would provide
a foundation for each child to grow in conﬁdence and esteem.
 Family care and support is essential throughout child-
hood with support and social care assistance where
required. Schools should be provided with specialist
information about the care and management of a child
with DM1. A social work consult or a referral to nursing
case management can also be beneﬁcial for patients. A
holistic approach is critical because the aﬀected parent
may also need additional assistance.
 Families should have access to disability beneﬁts,
adequate housing and adaptations during the progression
of the condition.
Excessive daytime sleepiness
 Family members and educators should be educated about
the EDS that comes with DM1.
 Children should be screened for signs of EDS, including
prolonged naps or falling asleep in school.
 Possible sleep apnea should be evaluated with overnight
oximetry or polysomnogram.
 Positive-pressure ventilation can be considered if a DM1
patient’s sleepiness is thought to be related to nocturnal
or daytime hypoventilation or sleep apnea. Patients
should be referred to pulmonologists who have experi-
ence in neuromuscular diseases for consideration of
assisted ventilation.
 Stimulant therapy with a psychostimulant such as
modaﬁnil (Provigil), methylphenidate, or other stimulant
can be considered if central hypersomnia is suspected.
Often diﬃculty staying awake in school is a triggering
factor. Special care should be taken in children with
previously detected cardiac arrhythmia (See Cardiac
section on stimulant management).
Endocrine and metabolism
c DM1 male patients should undergo a detailed physical
examination in search of gonadal atrophy or cryptorchidism.
c Patients should have a HbA1c and thyroid-stimulating
hormone and Free T4 level measured at baseline and
every 3 years, or if there is a clinical suspicion.
c Adolescent patients should be screened as adult patients:
◦ Gonadal insuﬃciency and complications of the
reproductive system: Inquiring about amenorrhea
or dysmenorrhea for the female patients, and erectile
dysfunction for male patients
◦ Fasting blood lipids, plasma glucose, liver enzymes,
bilirubin levels, and gamma-glutamyl transpeptidase
should be measured at baseline.
Conclusions
The recommendations for care of congenital and childhood-
onset myotonic dystrophy have been created by consensus of
clinicians experienced in their care management. Given the
absence of rigorous studies in many of these areas, these
guidelines were created by consensus. They are designed to
standardize the care of children with a multisystemic disorder
that leads to signiﬁcant morbidity and mortality.
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